ALLMedicine™ Hypogammaglobulinemia Center
Research & Reviews 403 results
https://doi.org/10.1007/s00277-021-04662-1 10.1016/j.cell.2021.01.007 10.1016/j.cell.2020.09.038 10.1200/JCO.1998.16.8.2825 10.1080/10428190902730219 10.1002/jmv.25988 10.1016/j.jcv.2020.104305 10.1128/JCM.02955-20 10.1016/j.jcv.2020.104688 10.1126/science.abd7728 10.1007/s00134-020-05991-x 10.1016/j.ijid.2020.04.086 10.1038/s41598-020-77945-8 10.1111/bjh.16896 10.1126/sciimmunol.abf3698 10.1111/pai.13263 10.1016/j.msard.2020.102120 10.1177/1352458520943791 10.1172/jci.insight.123158 10.1016/s2665-9913(20)30270-8 10.4049/jimmunol.1004095 10.1212/WNL.0000000000010380 10.1002/art.25034 10.1093/cid/cit816 10.1111/cei.13495 10.1186/s13045-020-00968-1
Annals of Hematology; Levavi H, Lancman G et. al.
Sep 23rd, 2021 - Rituximab is associated with prolonged B-cell depletion and secondary hypogammaglobulinemia and is associated with a dampened humoral response and increased infectious complications. To describe the potential impact of prior rituximab therapy on c...
https://doi.org/10.1182/bloodadvances.2020004079
Blood Advances; Kambhampati S, Sheng Y et. al.
Sep 21st, 2021 - B-cell maturation antigen-targeted chimeric antigen receptor T cell therapy (BCMA CAR-T) is an effective treatment for relapsed refractory multiple myeloma (RRMM). However the pattern of infectious complications is not well-elucidated. We performe...
https://doi.org/10.1007/s00277-021-04649-y 10.1038/s41409-020-0826-4 10.1038/s41409-019-0624-z 10.1038/sj.bmt.1705892 10.1517/14712598.8.5.583 10.3389/fimmu.2016.00507 10.6004/jnccn.2012.0146 10.1016/j.bbmt.2009.06.019 10.1007/s10875-017-0469-4 10.1007/s00277-016-2711-1 10.1002/14651858.CD006501.pub2 10.1016/j.bbmt.2014.12.001 10.1016/j.bbmt.2015.09.001 10.1097/00007890-197410000-00001 10.1016/S1473-3099(18)30600-5 10.1038/bmt.2014.28 10.1038/bmt.2013.76 10.1016/j.leukres.2015.10.013 10.1016/j.bbmt.2017.08.010 10.3389/fimmu.2019.00033 10.1016/j.jaci.2016.09.023 10.1016/j.jaci.2006.01.015 10.1016/j.blre.2017.09.003 10.1093/annonc/mdv303 10.1111/cei.12915 10.1093/jac/dkx324 10.1093/ndt/gfu023 10.3389/fimmu.2016.00500 10.1038/sj.bmt.1703185 10.7326/0003-4819-139-1-200307010-00007 10.1016/j.bbmt.2007.10.009 10.1592/phco.20.15.1175.34592 10.21873/anticanres.12712 10.1016/j.jaci.2012.06.021
Annals of Hematology; Karakulska-Prystupiuk E, Dwilewicz-Trojaczek J et. al.
Sep 4th, 2021 - Secondary immunodeficiencies are frequently observed after allo-HSCT. The efficacy of subcutaneous IgG preparations in this population is unknown. A retrospective single-institution study involved 126 adult patients transplanted in 2012-2019 for h...
https://doi.org/10.1016/j.clim.2021.108837
Clinical Immunology (Orlando, Fla.); Papa R, Rusmini M et. al.
Aug 30th, 2021 - RAS-associated autoimmune leukoproliferative disease (RALD) is a rare immune dysregulation syndrome caused by somatic gain-of-function mutations of either NRAS or KRAS gene in hematopoietic cells. We describe a 27-year-old patient presenting at 5 ...
https://doi.org/10.1007/s10875-021-01123-2 10.1182/blood.2018885244 10.1073/pnas.0610289104 10.1016/S1081-1206(10)60066-X 10.1038/nature11247 10.1186/s13059-017-1285-0 10.4049/jimmunol.1900650 10.1097/COH.0000000000000094 10.1016/j.immuni.2014.01.005 10.18632/aging.102438 10.1261/rna.075929.120 10.1182/blood-2014-06-582700 10.3389/fimmu.2018.01730 10.1093/intimm/dxx048 10.3389/fimmu.2019.00753 10.1002/art.39020 10.1186/s12865-020-00379-4 10.1016/j.jaut.2006.07.005 10.1111/j.1365-2249.2009.04007.x 10.1038/s41467-018-07766-x 10.1038/ncomms11688 10.1002/art.34400
Journal of Clinical Immunology; Zhang Z, Shi L et. al.
Aug 27th, 2021 - Chromosome 22q11.2 deletion syndrome is a common inborn error of immunity. The early consequences of thymic hypoplasia are low T cell numbers. Later in life, atopy, autoimmunity, inflammation, and evolving hypogammaglobulinemia can occur and the c...
Drugs 2 results see all →
Clinicaltrials.gov 1 results
https://clinicaltrials.gov/ct2/show/NCT02680652
Abstract: An increased susceptibility to bacterial and viral infections is the hallmark of explain the study rationale, primary immunodeficiencies (PID). The most common PID requiring treatment with Ig replacement (SCIg or IVIg) is Common Variable...
News 19 results
https://www.medscape.com/viewarticle/950765
May 7th, 2021 - The serious infection risk associated with rituximab treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is high but can be offset by co-prescribing co-trimoxazole, data from a single-center, retrospective study re...
https://www.medscape.com/viewarticle/949577
Apr 20th, 2021 - A quarter of children receiving treatment with rituximab developed hypogammaglobulinemia within 18 months of starting the drug, according to preliminary research shared at the annual scientific meeting of the Childhood Arthritis and Rheumatology R...
https://www.medscape.com/viewarticle/939605
Oct 22nd, 2020 - Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with immunomodulatory agents harbored gene variants associated with inborn errors of immunity, according to the find...
https://www.staging.medscape.com/viewarticle/939605
Oct 22nd, 2020 - Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with immunomodulatory agents harbored gene variants associated with inborn errors of immunity, according to the find...
https://www.mdedge.com/clinicianreviews/article/209354/infectious-diseases/ipd-children-may-be-signal-immunodeficiency?channel=284
Bianca Nogrady
Oct 3rd, 2019 - Recurrent invasive pneumococcal disease in children could be a signal of underlying primary immunodeficiency, according to a systematic review published in JAMA Pediatrics. Coen Butters, BMed, DCH, of the Royal Children’s Hospital in Melbourne, an.
